The recent paper by Lim et al is complementary and supportive of the present study, demonstrating that in vivo inhibition of the C5a-C5aR pathway, using receptor-selective antagonists of C5aR, improved the presentation of metabolic syndrome in diet-induced obese rats, with less increase in body weight, visceral fat and adiposity as well as showing improvements in glucose and insulin resistance [31]. Here, C5AR1 is linked to metabolic syndrome.